PRTK - Paratek Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Paratek Pharmaceuticals, Inc.

75 Park Plaza
4th Floor
Boston, MA 02116
United States
617-807-6600
http://paratekpharma.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees48

Key Executives

NameTitlePayExercisedAge
Mr. Michael F. Bigham CPA, MBAChairman and Chief Exec. Officer663.43kN/A59
Dr. Evan Loh M.D., FACC, FAHAPres, Chief Medical Officer, COO & Director620.78kN/A58
Mr. Douglas W. Pag??nChief Financial Officer457.82kN/A45
Mr. William M. HaskelSr. VP, Gen. Counsel and Corp. Sec.569.77kN/A55
Mr. Adam WoodrowChief Commercial Officer and VP466.27kN/A50
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Paratek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, a broad-spectrum, intravenous, and oral antibiotic, which is in Phase III clinical stage for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound that is in Phase III clinical trial for the treatment of acne and rosacea. The company has special protocol assessment agreements with Food and Drug Administration for the Phase III studies for ABSSSI and CABP. It has collaborative research and license agreement with Allergan plc to research, develop, and commercialize tetracycline products; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and license agreement with Shin Nippon Biomedical Laboratories Ltd. to develop TO-2070 for the treatment of acute migraine. The company also has a cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.

Corporate Governance

Paratek Pharmaceuticals, Inc.’s ISS Governance QualityScore as of December 1, 2017 is 7. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 7; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.